Back to Search
Start Over
Real-world management patterns in EGFR-mutant advanced non-small-cell lung cancer before first-line adoption of osimertinib: the REFLECT study in Greece
- Source :
- Future Oncology. 18:3151-3164
- Publication Year :
- 2022
- Publisher :
- Future Medicine Ltd, 2022.
-
Abstract
- Aim: To retrospectively characterize real-world therapeutic strategies, clinical outcomes and attrition rates with EGFR tyrosine kinase inhibitors (TKIs), before first-line osimertinib approval, in EGFR-mutated advanced/metastatic non-small-cell lung cancer patients in Greece. Results: Among 160 patients, the discontinuation rate for first-line first- or second-generation EGFR-TKIs was 85%; among these patients, 43% did not receive any second-line therapy and 9.4% died during an 18.7-month follow-up period. Median progression-free and overall survival were 12.1 and 20.9 months, respectively. Osimertinib was offered as second- and third-line treatment in 69.6 and 21.7% of patients with the T790M mutation, respectively. Brain metastases were recorded in 10.6% of patients during treatment, with median overall survival of 4.9 months. Conclusion: Given the high attrition rates and the impact of CNS progression, offering the most appropriate first-line EGFR-TKI treatment with CNS penetration is key to maximize outcomes.
- Subjects :
- Cancer Research
Oncology
General Medicine
Subjects
Details
- ISSN :
- 17448301 and 14796694
- Volume :
- 18
- Database :
- OpenAIRE
- Journal :
- Future Oncology
- Accession number :
- edsair.doi...........fbb4e294a6459568630b3518a5e5d2b1